Brief: TCR2 Therapeutics Reports Q3 Loss Of $0.79 Per Share
08/11/2022 11:47
Nov 8 (Reuters) - Tcr2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* QTRLY LOSS PER SHARE $0.79
* CONTINUES TO PROJECT NET CASH USE OF $115-125 MILLION FOR
2022
* EXPECT CASH ON HAND TO SUPPORT OPERATIONS INTO 2024
* Q3 EARNINGS PER SHARE VIEW $-0.83 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4zXNpj
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview